A Shot For Bipolar I Disorder?

Watch the full webinar here: psychu.org/a-s...
Bipolar I Disorder is a chronic mental health condition. Recurrence of mood episodes and functional deterioration are related. A question that deserves further discussion is, “At what point is maintenance
therapy warranted?” In this webinar archive, Otsuka Senior MSL, Dr. Fatima Sadat, sits down with Drs. Mauricio Tohen and Joseph Goldberg to uncover issues related to identifying profiles of Bipolar I Disorder patients who may be considered for long acting injectable medication maintenance therapy.
Featuring:
• Mauricio Tohen, MD, DrPH, MBA
Professor and Chair, Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, New Mexico
• Joseph F. Goldberg, MD
Clinical Professor, Department of Psychiatry, Icahn School of Medicine, Mount Sinai, New York City, New York
• Fatima Sadat, PharmD
Senior Medical Science Liaison, Otsuka Pharmaceutical Development and Commercialization Inc.
Dr. Mauricio Tohen is a University Distinguished Professor and Chairman of the Department of Psychiatry & Behavioral Sciences at the University of New Mexico HSC in Albuquerque NM, USA. In 2014 Dr Tohen was recognized in Thomson Reuter’s “The World’s Most Influential Scientific Minds. He is 1 of 100 scientists worldwide recognized in the Psychiatry/psychology category. Dr Tohen has published over 350 publications and has over 20,000 scientific citations. In 2016, the International Society for Bipolar disorders awarded him the Mogens Schou award for Education and Teaching.
Dr. Joseph F. Goldberg is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. Dr .Goldberg serves on the Board of Directors for the American Society of Clinical Psychopharmacology and has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology.
#MentalHealth #Bipolar #PsychU
Dr. Mauricio Tohen and Dr. Joseph F. Goldberg are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Fatima Sadat, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC - committed supporters of the mental health
treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
US.CORP.X.21.00180 / US.CORP.X.21.00144